Global 3D Bioprinting for Life Science R&D Market Insights, Size, and Forecast By Technology (Extrusion-based Bioprinting, Laser-assisted Bioprinting, Inkjet Bioprinting, Stereolithography, Combination Bioprinting), By Material Type (Bioinks, Cells, Nanofibers, Hydrogels, Scaffolds), By End User (Academic Institutions, Research Laboratories, Pharmaceutical Companies, Biotechnology Firms), By Application (Tissue Engineering, Drug Testing, Organ Printing, Cell Culture, Research & Development), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Key Market Insights
Global 3D Bioprinting for Life Science R&D Market is projected to grow from USD 2.8 Billion in 2025 to USD 14.5 Billion by 2035, reflecting a compound annual growth rate of 17.4% from 2026 through 2035. This market encompasses the design and fabrication of biological constructs using 3D printing techniques for research and development across various life science applications. It involves the precise deposition of biomaterials, cells, and biochemicals to create functional tissues and organs. The market is primarily driven by the increasing demand for advanced drug discovery and development platforms, the growing need for organ transplantation alternatives, and the rising prevalence of chronic diseases necessitating novel therapeutic approaches. Furthermore, significant advancements in biomaterial science, cell biology, and 3D printing technologies are fueling market expansion. Important trends include the development of multi-material bioprinting, in situ bioprinting for direct tissue repair, and the integration of artificial intelligence and machine learning to optimize bioprinting processes and accelerate research outcomes.
Global 3D Bioprinting for Life Science R&D Market Value (USD Billion) Analysis, 2025-2035
2025 - 2035
www.makdatainsights.com
Despite the promising outlook, the market faces several restraints. High initial investment costs for 3D bioprinting equipment and specialized biomaterials pose a barrier for smaller research institutions and startups. Regulatory complexities and the absence of standardized protocols for bioprinted constructs also hinder widespread adoption and commercialization. Ethical concerns surrounding the creation of artificial organs and tissues present another challenge. However, substantial market opportunities exist in the development of personalized medicine, regenerative therapies for complex conditions, and the creation of accurate human disease models for preclinical testing, reducing reliance on animal models. The market is segmented by application, technology, material type, and end user, allowing for targeted innovation and specialization.
North America currently dominates the 3D bioprinting for life science R&D market due to robust research infrastructure, significant funding for biotechnological advancements, and the presence of numerous key market players and academic institutions engaged in cutting-edge research. Conversely, Asia Pacific is anticipated to be the fastest growing region, driven by increasing government support for life science research, a burgeoning pharmaceutical and biotechnology industry, and a growing pool of skilled researchers. Key players in this dynamic market include 3D Biotek, Allevi, BICO, Organovo, Panaceutics, CELLINK, Aspect Biosystems, Materialise, Stratasys, and T752. These companies are actively engaged in strategic collaborations, product innovation, and expanding their geographical footprint to capitalize on emerging opportunities and consolidate their market positions, with a strong focus on enhancing bioprinting precision and developing novel bioinks. The leading application segment is drug testing, reflecting the critical need for more accurate and predictive in vitro models for pharmaceutical development.
Quick Stats
Market Size (2025):
USD 2.8 BillionProjected Market Size (2035):
USD 14.5 BillionLeading Segment:
Drug Testing (38.5% Share)Dominant Region (2025):
North America (38.7% Share)CAGR (2026-2035):
17.4%
What is 3D Bioprinting for Life Science R&D?
3D Bioprinting for Life Science R&D involves using additive manufacturing to create biological constructs layer by layer. This technology precisely deposits biomaterials, living cells, and growth factors to fabricate complex tissues and organs or model systems. Its core concept is to mimic natural biological structures and functions in a controlled laboratory setting. Significance lies in its ability to accelerate drug discovery by creating more accurate disease models, advance regenerative medicine by engineering transplantable tissues, and enable fundamental research into cell biology and tissue development, ultimately reducing animal testing and improving human health outcomes.
What are the Trends in Global 3D Bioprinting for Life Science R&D Market
Organoid Biofabrication for Drug Discovery Acceleration
AI Driven Bioprinting for Personalized Medicine
In Situ Bioprinting for Regenerative Therapies
Multi Material Bioprinting for Complex Tissue Engineering
Organoid Biofabrication for Drug Discovery Acceleration
Organoid biofabrication streamlines drug discovery by creating realistic human tissue models. These patient specific 3D organoids enable more accurate disease modeling and drug screening, accelerating the identification of effective therapeutics. It significantly reduces reliance on animal models and improves drug candidate selection, leading to faster development cycles and earlier market access for innovative medicines. This trend marks a shift towards more predictive and efficient preclinical testing methodologies.
AI Driven Bioprinting for Personalized Medicine
AI algorithms are revolutionizing bioprinting, enabling the precise creation of patient specific tissues and organs. This integration enhances the speed, accuracy, and complexity of fabricating living structures. Machine learning personalizes bioinks and scaffold designs, optimizing cellular viability and functionality. This advancement promises bespoke implants and drug testing models, accelerating the delivery of truly individualized therapies and regenerative solutions.
In Situ Bioprinting for Regenerative Therapies
In situ bioprinting revolutionizes regenerative therapies by enabling direct, on demand fabrication of living tissues and organs within the body. This trend minimizes surgical invasiveness, accelerates healing, and precisely delivers cells and biomaterials directly to injury sites. It holds immense promise for personalized medicine and treating complex tissue defects, bypassing ex vivo culturing challenges.
Multi Material Bioprinting for Complex Tissue Engineering
Multi material bioprinting addresses the complexity of native tissues by enabling precise placement of diverse bioinks. This innovation allows engineers to simultaneously print various cell types, growth factors, and biomaterials with distinct mechanical and biochemical properties. The goal is to fabricate more functional and viable constructs, accelerating development of intricate organs and tissues for regenerative medicine and drug screening.
What are the Key Drivers Shaping the Global 3D Bioprinting for Life Science R&D Market
Advancements in Bioprinting Technologies and Materials
Increasing Funding and Investments in Regenerative Medicine and Tissue Engineering
Growing Demand for Personalized Medicine and Organ-on-a-Chip Models
Expanding Applications in Drug Discovery, Toxicology, and Disease Modeling
Advancements in Bioprinting Technologies and Materials
Innovations in bioprinting hardware and software, alongside development of novel bioinks like hydrogels and cell laden materials, are fueling growth. These advancements enable greater precision, speed, and complexity in fabricating tissues and organs, accelerating research and development across various life science applications, including drug discovery, toxicology, and regenerative medicine.
Increasing Funding and Investments in Regenerative Medicine and Tissue Engineering
Growing private and public funding, along with increased venture capital investments, significantly fuels research and development in regenerative medicine and tissue engineering. This financial injection supports technological advancements, clinical trials, and commercialization efforts for 3D bioprinting applications. It accelerates innovation and expands the range of printable tissues and organs, driving market growth by enabling new scientific breakthroughs and therapeutic solutions.
Growing Demand for Personalized Medicine and Organ-on-a-Chip Models
Rising prevalence of chronic diseases and the need for more accurate drug discovery models are driving demand for personalized medicine. 3D bioprinting offers a revolutionary approach to creating patient specific tissues and organ on a chip models. This enables better understanding of disease progression and drug efficacy, accelerating the development of tailored therapies and reducing animal testing.
Expanding Applications in Drug Discovery, Toxicology, and Disease Modeling
3D bioprinting's growing utility across drug discovery, toxicology screening, and disease modeling accelerates its adoption. Researchers leverage this technology to create more accurate in vitro models, enabling better prediction of drug efficacy and safety. This expanding application base fuels demand for bioprinting solutions, driving market growth as it revolutionizes preclinical research and personalized medicine development.
Global 3D Bioprinting for Life Science R&D Market Restraints
High Capital Expenditure and Operational Costs for 3D Bioprinting Systems
High capital outlay for advanced 3D bioprinting systems presents a significant barrier to entry and expansion for many institutions. Acquisition costs for sophisticated hardware, specialized biomaterials, and necessary software are substantial. Furthermore, ongoing operational expenses like maintenance, calibration, power consumption, and the continuous purchase of high-purity bioinks and reagents add to the financial burden. These considerable expenditures restrict widespread adoption, particularly for smaller research facilities or startups with limited budgets, thus impeding market growth and technological diffusion in life science R&D.
Regulatory Hurdles and Ethical Concerns for Bioprinted Tissues and Organs
Developing bioprinted tissues faces significant regulatory and ethical challenges. Strict approval processes are required due to safety concerns, particularly regarding long-term viability and potential immune responses in recipients. Ethical debates surrounding the creation and use of human tissues, potential for misuse, and informed consent for research also contribute to these hurdles, slowing commercialization and widespread adoption in healthcare.
Global 3D Bioprinting for Life Science R&D Market Opportunities
Accelerating Drug Discovery & Toxicology with Advanced 3D Bioprinted Organ-on-Chip Models
This opportunity harnesses advanced 3D bioprinted organ on chip models to revolutionize drug discovery and toxicology. These sophisticated biomimetic systems offer superior accuracy and physiological relevance compared to traditional methods. They enable rapid, reliable screening of drug candidates, substantially shortening development timelines and reducing costs. By providing a more human like test environment, these models mitigate animal testing requirements, accelerating the identification of safer, more effective therapeutics. This innovation significantly propels life science research forward.
Enabling Personalized Medicine R&D through High-Fidelity 3D Bioprinted Tissue and Organoid Systems
This opportunity focuses on leveraging high fidelity 3D bioprinted tissue and organoid systems to transform personalized medicine R&D. These advanced models accurately mimic human physiology and disease, enabling predictive drug screening, toxicity testing, and patient specific disease modeling. They accelerate the discovery of targeted therapies by offering human relevant *in vitro* platforms. This reduces reliance on animal models and clinical trial failures, while enhancing precision in drug development. It drives significant innovation, allowing researchers to create bespoke treatment strategies and improve patient outcomes globally within life sciences.
Global 3D Bioprinting for Life Science R&D Market Segmentation Analysis
Key Market Segments
By Application
- •Tissue Engineering
- •Drug Testing
- •Organ Printing
- •Cell Culture
- •Research & Development
By Technology
- •Extrusion-based Bioprinting
- •Laser-assisted Bioprinting
- •Inkjet Bioprinting
- •Stereolithography
- •Combination Bioprinting
By Material Type
- •Bioinks
- •Cells
- •Nanofibers
- •Hydrogels
- •Scaffolds
By End User
- •Academic Institutions
- •Research Laboratories
- •Pharmaceutical Companies
- •Biotechnology Firms
Segment Share By Application
Share, By Application, 2025 (%)
- Drug Testing
- Tissue Engineering
- Research & Development
- Cell Culture
- Organ Printing
www.makdatainsights.com
Why is Drug Testing dominating the Global 3D Bioprinting for Life Science R&D Market?
The significant share held by Drug Testing stems from the urgent need for more accurate and efficient methods in pharmaceutical research. 3D bioprinting enables the creation of complex 3D tissue models that closely mimic human physiology, offering a superior alternative to traditional 2D cell cultures and animal models. This capability reduces the high failure rates of drugs in clinical trials, accelerates the drug discovery process, and provides a more ethical testing platform. Its potential to generate physiologically relevant disease models for screening novel compounds makes it an invaluable tool for pharmaceutical companies and research laboratories seeking to optimize drug development workflows.
How do different technology segments influence the adoption of 3D bioprinting in R&D?
Each technology segment caters to specific research needs and fabrication complexities. Extrusion based bioprinting, known for its versatility and ability to handle a wide range of bioinks and cell types, often serves as a foundational technology in many research settings. Laser assisted bioprinting and Inkjet bioprinting offer higher precision and resolution, crucial for delicate cell patterning and creating intricate microstructures. Stereolithography excels in fabricating complex structures with excellent mechanical properties. The choice of technology directly impacts the fidelity of the bioprinted constructs, influencing outcomes in tissue engineering, organ printing, and advanced cell culture applications.
What role do Bioinks play in driving innovation across the 3D bioprinting landscape?
Bioinks are fundamental to the advancement and functionality of 3D bioprinting within life science R&D. These specialized materials, comprising cells and biocompatible polymers like hydrogels or nanofibers, serve as the building blocks for creating functional tissues and organs. Their importance lies in their ability to provide a suitable microenvironment for cell viability, proliferation, and differentiation. Ongoing research into novel bioink formulations with enhanced biological cues and mechanical properties is crucial for pushing the boundaries of what can be bioprinted, directly impacting the success and biological relevance of constructs used in drug testing, regenerative medicine, and disease modeling studies.
What Regulatory and Policy Factors Shape the Global 3D Bioprinting for Life Science R&D Market
The global 3D bioprinting R&D market navigates a complex and evolving regulatory landscape. National bodies like the FDA EMA and PMDA classify bioprinted constructs as medical devices biologics or combination products. This multifaceted nature demands rigorous safety efficacy and quality control assessments, particularly for human cell derived materials. Harmonization across different regions remains a significant challenge, leading to diverse approval pathways and impacting global market access. Ethical considerations surrounding donor tissue procurement and intellectual property further shape policy development. Governments are actively developing specific guidance documents to address this emerging technology. Navigating this dynamic regulatory environment is crucial for research translation and commercialization success.
What New Technologies are Shaping Global 3D Bioprinting for Life Science R&D Market?
The global 3D bioprinting market for life science R&D is experiencing robust growth driven by groundbreaking innovations. Emerging technologies include advanced bioinks with enhanced biocompatibility and functional properties, enabling the creation of more complex and viable tissue constructs. High resolution multi material bioprinting techniques are crucial for replicating intricate organ architectures, improving models for drug discovery and disease research. Artificial intelligence and machine learning are increasingly integrated to optimize print parameters and design sophisticated tissue engineering scaffolds. Volumetric bioprinting and microfluidic approaches are accelerating the development of functional organ on a chip platforms. This transformative sector is rapidly advancing personalized medicine and regenerative solutions.
Global 3D Bioprinting for Life Science R&D Market Regional Analysis
Global 3D Bioprinting for Life Science R&D Market
Trends, by Region
North America Market
Revenue Share, 2025
www.makdatainsights.com
North America dominates the global 3D Bioprinting for Life Science R&D market, holding a substantial 38.7% share. This leadership is driven by significant investments in R&D, a robust presence of key market players and academic institutions, and advanced healthcare infrastructure. The region benefits from strong governmental support for biomedical research and a high adoption rate of innovative technologies. The concentration of pharmaceutical and biotechnology companies further fuels market expansion, with ongoing advancements in regenerative medicine and tissue engineering creating substantial opportunities for growth and innovation across theS U.S. and Canada.
Europe is a crucial hub for 3D bioprinting R&D, driven by strong government funding and collaborative academic-industrial partnerships. Germany and the UK lead in research publications and patent applications, leveraging robust biomedical and engineering infrastructure. Nordic countries show significant innovation in regenerative medicine applications. France focuses on tissue engineering and personalized medicine. Eastern European nations are emerging, capitalizing on lower operational costs and skilled scientific workforces. Regulatory frameworks are evolving across the continent, impacting market growth and commercialization. The region's aging population and high healthcare expenditure further fuel demand for advanced bioprinting solutions in life science R&D.
Asia Pacific emerges as the fastest-growing region in the 3D bioprinting for life science R&D market, projected at a robust 24.8% CAGR. This surge is fueled by increasing government funding for biomedical research, a burgeoning biotechnology sector, and a rise in chronic diseases driving demand for advanced regenerative medicine solutions. Countries like China, Japan, and South Korea are at the forefront, investing heavily in research infrastructure and attracting foreign investment. The region's large patient pool and growing academic-industrial collaborations further propel market expansion, positioning APAC as a critical hub for innovation in bioprinting technologies.
Latin America's 3D bioprinting market for life science R&D is nascent but growing. Brazil leads due to significant government and private investment in biomedical research and a developing biotech sector. Mexico follows, leveraging its proximity to the US and growing medical device industry. Argentina, despite economic challenges, has a strong scientific base driving innovation. Chile and Colombia are emerging, supported by increasing R&D funding and academic collaborations. Key drivers across the region include rising chronic disease prevalence, increasing demand for personalized medicine, and government initiatives promoting advanced manufacturing. Challenges include limited funding, lack of skilled personnel, and regulatory hurdles.
The MEA 3D bioprinting market for life sciences R&D is emerging, driven by increasing government investments in healthcare infrastructure and rising demand for advanced regenerative medicine. South Africa leads with robust research institutions and growing biomedical industries. UAE and Saudi Arabia are rapidly investing in healthcare biotechnology, aiming to become regional hubs. Challenges include limited skilled professionals and high initial investment costs. However, growing awareness of personalized medicine and increasing collaborations with international research organizations are expected to fuel significant growth, particularly in tissue engineering and drug discovery applications. Regional research focuses on disease modeling relevant to indigenous populations.
Top Countries Overview
The US leads global 3D bioprinting for life science R&D. Its market thrives on academic research, pharmaceutical innovation, and a robust startup ecosystem. Significant investment drives advancements in tissue engineering, drug discovery, and regenerative medicine, positioning the US at the forefront of this transformative biomedical technology.
China significantly influences the global 3D bioprinting market for life science R&D. Its substantial investment in biotechnology, increasing government support for innovation, and rapidly expanding research infrastructure position it as a key driver. Chinese companies and institutions are actively advancing bioprinting technologies, contributing to therapeutic and diagnostic applications globally.
India’s global 3D bioprinting market for life science R&D is rapidly expanding. It leverages a large scientific talent pool and government support, becoming a key player in regenerative medicine and drug discovery. Challenges include regulatory frameworks and infrastructure, yet growth is strong, propelled by rising healthcare demand and technological advancements.
Impact of Geopolitical and Macroeconomic Factors
Geopolitical stability drives research investment, particularly in advanced biotech like 3D bioprinting. Trade policies concerning medical devices and biological materials significantly impact market accessibility and raw material costs. Intellectual property rights protection across jurisdictions is crucial for innovation and technology transfer, while international collaborations foster market expansion and knowledge sharing, influencing market growth.
Macroeconomic conditions, including R&D budgets and healthcare spending, directly influence market demand. Inflationary pressures can increase operational costs for bioprinting companies and research institutions. Venture capital availability and government funding for life sciences are vital for startups and technology development. Regulatory frameworks regarding biomaterials and bioprinted tissues also shape market trajectory and adoption.
Recent Developments
- March 2025
BICO announced a strategic partnership with Panaceutics to integrate advanced bioprinting solutions with high-throughput drug screening platforms. This collaboration aims to accelerate the development and testing of new therapeutic compounds using 3D tissue models.
- January 2025
CELLINK launched a new high-resolution bioprinter, 'BioVerse Pro,' specifically designed for complex organ-on-a-chip and microfluidic applications. This system offers enhanced precision and multi-material printing capabilities, catering to advanced life science research.
- November 2024
Aspect Biosystems completed a Series B funding round, raising significant capital to scale up its proprietary bioprinting technology for human tissue therapeutics. The investment will primarily support expanded R&D efforts and clinical translation of their biofabricated tissues.
- April 2025
Organovo acquired a specialized bioink manufacturing company, enhancing its in-house capabilities for developing next-generation biomaterials tailored for various tissue engineering applications. This acquisition strengthens Organovo's vertical integration and control over critical supply chain components.
- February 2025
Allevi introduced a new software suite, 'Allevi Architect 2.0,' featuring AI-driven design tools and advanced print path optimization for 3D bioprinting. This update aims to simplify experimental setup and improve reproducibility in tissue engineering research.
Key Players Analysis
Key players like BICO and CELLINK are dominating the Global 3D Bioprinting for Life Science R&D Market through innovative bioprinters and bioinks. Organovo and Aspect Biosystems focus on developing functional human tissues using advanced extrusion and microfluidic technologies, respectively. Materialise and Stratasys contribute with their expertise in hardware and software for precise 3D printing, supporting complex R&D applications. Companies like 3D Biotek and Allevi are expanding their offerings through strategic partnerships and continuous R&D into novel materials and methods. Market growth is driven by the increasing demand for in vitro models, drug discovery, and regenerative medicine, pushing these companies to invest in automation and high throughput solutions.
List of Key Companies:
- 3D Biotek
- Allevi
- BICO
- Organovo
- Panaceutics
- CELLINK
- Aspect Biosystems
- Materialise
- Stratasys
- T752
- Regenhu
- EnvisionTEC
Report Scope and Segmentation
| Report Component | Description |
|---|---|
| Market Size (2025) | USD 2.8 Billion |
| Forecast Value (2035) | USD 14.5 Billion |
| CAGR (2026-2035) | 17.4% |
| Base Year | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2035 |
| Segments Covered |
|
| Regional Analysis |
|
Table of Contents:
List of Figures
List of Tables
Table 1: Global 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 2: Global 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Technology, 2020-2035
Table 3: Global 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Material Type, 2020-2035
Table 4: Global 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 5: Global 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Region, 2020-2035
Table 6: North America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 7: North America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Technology, 2020-2035
Table 8: North America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Material Type, 2020-2035
Table 9: North America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 10: North America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Country, 2020-2035
Table 11: Europe 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 12: Europe 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Technology, 2020-2035
Table 13: Europe 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Material Type, 2020-2035
Table 14: Europe 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 15: Europe 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 16: Asia Pacific 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 17: Asia Pacific 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Technology, 2020-2035
Table 18: Asia Pacific 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Material Type, 2020-2035
Table 19: Asia Pacific 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 20: Asia Pacific 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 21: Latin America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 22: Latin America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Technology, 2020-2035
Table 23: Latin America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Material Type, 2020-2035
Table 24: Latin America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 25: Latin America 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 26: Middle East & Africa 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 27: Middle East & Africa 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Technology, 2020-2035
Table 28: Middle East & Africa 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Material Type, 2020-2035
Table 29: Middle East & Africa 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 30: Middle East & Africa 3D Bioprinting for Life Science R&D Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035